Dapagliflozin is a selective inhibitor of sodium–glucose cotransporter 2 (SGLT2) that blocks glucose resorption in the proximal tubule of the kidney and promotes glucosuria. 11-13 Other SGLT2 ...

Dapagliflozin was stopped for reasons other than death in 249 patients and placebo was stopped in 258 patients (10.5% vs. 10.9%, P=0.71). At the last assessment, ...

Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis ...

Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...

Farxiga is a prescription oral tablet used to manage type 2 diabetes or certain heart or kidney conditions. It’s a brand-name drug with the active ingredient dapagliflozin. Farxiga tablets come ...

Dapagliflozin produces a dose-dependent and sustained reduction in both fasting and postprandial serum glucose levels through increased urinary glucose excretion, ...

Dapagliflozin 10 mg also resulted in greater weight loss than did metformin (P < .0001). Events suggestive of genital infection were reported in 6.7%, 6.9%, ...

Dapagliflozin was well-tolerated, with no new safety issues identified. There were fewer serious adverse events in the dapagliflozin group vs. placebo (65 vs. 82). COVID-19 ‘not stable disease’ ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...